Introduction
Significant advances in perinatal care have been achieved over the past three decades. Despite this, preterm birth rates continue to increase in the United States. 1, 2 Respiratory distress syndrome (RDS) is the leading cause of respiratory insufficiency and is a major cause of mortality and morbidity in preterm infants. Incidence of RDS is inversely proportional to gestational age at birth. Pathophysiology of RDS is characterized by insufficient production of a surface-active agent, namely, surfactant. Surfactant is the first drug developed specifically for treatment of preterm neonates with RDS. Surfactant therapy has become the standard of care in the management of RDS. Human surfactant is primarily composed of dipalmitoylphosphatidylcholine (DPPC) and surfactant proteins (SP), SP-A, SP-B, SP-C and SP-D. Among these four surfactant proteins, two hydrophobic proteins, SP-B and SP-C, play a crucial role in the adsorption and spread of the DPPC at the air-liquid interphase in the lungs. In addition, an antioxidant phospholipid, plasmalogen, has been shown to work synergistically with surfactant-associated hydrophobic proteins in the spreading of DPPC, thus maintaining lower surface tension and alveolar stability at the end of expiration. 3, 4 SP-A and SP-D are lectin proteins that help to maintain sterility in the lung, whereas SP-B and SP-C help to maintain stability in the lung. None of the surfactant preparations contain SP-A or SP-D. Natural, modified surfactants derived from bovine or porcine lungs contain different amounts of SP-B, SP-C and plasmalogens. Animal-derived as well as synthetic surfactants, which are completely devoid of SP-B, SP-C and plasmalogens, have been extensively evaluated in preterm infants with RDS. Three animal-derived surfactant preparations used worldwide include beractant (BE) (Survanta, Abbott Laboratories Inc., Columbus, OH, USA), calfactant (CA) (Infasurf, Forest Laboratories, St Louis, MO, USA) and poractant alfa (PA) (Curosurf, Dey, LP, Napa, CA, USA). Synthetic surfactants that have been evaluated in comparative trials include colfosceril palmitate (Exosurf, Research Triangle Park, NC, USA), pumactant (ALEC, Britannia Pharmaceuticals, Crawley, UK) and lucinactant (Surfaxin, Discovery Laboratories, Doylestown, PA, USA).
Natural vs synthetic-surfactant studies
Fourteen trials comparing animal-derived surfactants with synthetic surfactants have been published (Table 1) . [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] To date, treatment with animal-derived surfactant preparations has been shown to result in better clinical response during the acute phase of RDS as evidenced by rapid weaning of inspired oxygen, mean airway pressure and lower air leaks when compared with treatment with synthetic preparations. Furthermore, neonatal mortality has also been shown to be lower among infants treated with a porcinederived surfactant when compared with those treated with pumactant, a synthetic preparation. 16 Ainsworth et al. 16 compared the porcine-derived surfactant, PA, with pumactant. This trial was stopped by the data and safety monitoring committee, because mortality assumed greater importance than the primary outcome. Mortality was significantly lower (14.1 vs 31%, P ¼ 0.006; odds ratio 0.37; 95% confidence interval [0.18, 0.76]) in the PA-treated infants. This difference was sustained after adjusting for gestational age, birth weight, gender, center, plurality and use of antenatal steroids. This was the first randomized, controlled trial that showed a survival advantage for an animal-derived surfactant preparation over that for a synthetic surfactant. However, survival advantage was a secondary endpoint in this trial. The incidence of bronchopulmonary dysplasia was not different with either animal-derived or synthetic surfactants. In the only trial 17 that compared two different synthetic preparations, bronchopulmonary dysplasia was significantly lower with lucinactant therapy when compared with colfosceril palmitate. In this prophylaxis trial, BE was included as a reference arm. A total of 1294 preterm infants, weighing 600 to 1250 g, were included; 509 infants received colfosceril palmitate, 527 received lucinactant and 258 infants received BE, within 20 to 30 min of birth. Even though the trial was designed as a prophylaxis trial, investigators allowed up to 30 min for administration of surfactants. This is because of the fact that lucinactant is a gel at both room and body temperature, and had to be warmed in a special warming cradle to 44 1C for 15 min. In all earlier, randomized, controlled prophylaxis trials, surfactant was typically administered within 10 to 15 min of birth. In the true sense, this trial 17 is an early rescue trial. Furthermore, comparison of outcomes between BE and lucinactant was of secondary interest, and this trial was not powered to detect efficacy against BE. Despite these limitations, there were no differences in the 14 variables that Animal-derived surfactantswere analyzed in this study between BE and lucinactant. In the second trial, 18 designed as a non-inferiority trial, comparing lucinactant with PA, no differences were found in 16 outcome variables analyzed between lucinactant-and PA-treated infants. There were several methodological problems with this trial. This study was stopped early because of slow recruitment after enrolling only 50.8% of the original sample size (252 out of 496 patients); mortality data chosen to assess non-inferiority was from a placebo-controlled treatment trial published 18 years before this trial; and the dose of PA used was not the dose used in the placebo-controlled trial. Survival at 1 year of corrected age was not different among the BE-treated group; 178/258 infants (69%) compared with 479/643 (75%) in the two trials 17, 18 with lucinactant treatment. 19 Similarly, survival at 1 year of corrected age among the PA-treated group was 97/124 infants (78%) compared with 479/643 (75%) in the two trials 17, 18 treated with lucinactant. 19 In a clinical report published in 2008, 20 the American Academy of Pediatrics and the Committee of the Fetus and Newborn (COFN) issued the following statement: 'FMore analysis is needed before the findings from lucinactant studies can be generalized because of questions about early trial closure and limited statistical power. Moreover, the metabolic fate of lucinactant and its component chemicals and potential risks introduced by the requirement to convert the lucinactant gel into liquid by using a special warming cradle immediately before instillation need additional study.' 20 In summary, results from randomized, controlled clinical trials show the superiority of animal-derived surfactant preparations over the synthetic surfactants that have been studied. At the time of this writing, there are no approved synthetic surfactants available for clinical use.
Animal-derived vs animal-derived surfactant studies Animal-derived surfactant preparations have been extensively evaluated for the treatment of RDS in preterm infants. Animal-derived surfactants differ in their source, method of preparation, composition, viscosity, dosing volume, phospholipid content, percentage of plasmalogens and amount of SP-B and SP-C 21-23 (Table 2 ). Minced as well as lavage preparations from bovine or porcine lungs are the three commonly used surfactants worldwide. BE is a minced bovine lung extract that contains lower amounts of phospholipids, plasmalogen and SP-B, compared with CA, which is a lavage preparation from bovine lungs. CA contains a higher amount of SP-B and phospholipids than does BE. Plasmalogen content in CA is not known. A lung lavage preparation from bovine lungs, used in Germany, namely, SF-RI1 (alveofact), contains the lowest amount of plasmalogens. Poractant alfa is a minced porcine surfactant that undergoes an additional step, liquid gel chromatography. As a result, PA contains only polar lipids and is more concentrated than the other animal-derived surfactants. In addition, PA contains the highest amount of plasmalogens. Higher plasmalogen content in the tracheal aspirates from preterm infants has been associated with a lower incidence of bronchopulmonary dysplasia. 24 Eight randomized, controlled clinical trials [25] [26] [27] [28] [29] [30] and two retrospective studies 31, 32 comparing the three natural surfactants have been reported. Four of the eight trials compared BE with CA 25, 26 and the remaining four trials [27] [28] [29] [30] compared BE with PA (Table 3 ). There are no prospective studies published comparing CA with PA.
Randomized trials comparing BE with CA In the four studies comparing BE with CA, 25, 26 treatment with CA was associated with a faster response during the acute phase of RDS in the rescue trial published in 1997. In the prophylaxis trial 25 comparing CA with BE published by the same investigators, mortality in infants <600 g in birth weight was significantly higher in the CA group when compared with that in the BE group (63 vs 26%, P ¼ 0.007). Overall mortality in the prevention trial was 8% in the BE group and 14% in the CA group (Figure 1 ). In the rescue trial, 25 mortality rates were 17% and 18% in the BE-and CA-treated groups, respectively (Figure 1 ). There were no significant differences in the percentage of infants requiring two or more surfactant doses in both these trials (Figure 2 ). In the remaining two large, but incomplete trials published in 2005, involving a total of 2110 preterm infants, no differences in mortality, need for additional doses, bronchopulmonary dysplasia or any other outcomes were shown. 26 Inadequate sample size from early trial closures prevented the investigators from accepting or rejecting null hypotheses. Sample sizes were calculated to show a difference of 6% in the primary outcome of infants alive at 36 weeks post-menstrual age and not receiving supplemental oxygen. Prophylaxis study was stopped after enrolling 749 of the 2000 infants in the original sample size and the rescue trial was also stopped after enrolling 1361 of 2080 infants. Overall mortality rates in the prophylaxis trial were 12% and 13%, and 10% and 11% in the treatment trial in the BE-and CA-treated groups, respectively ( Figure 1 ). There were no significant differences in the percentage of infants requiring two or more surfactant doses in both these trials, similar to the earlier comparative trials published 8 years before these two studies (Figure 2 ). In summary, there were no differences in mortality or dosing requirements reported in the four trials comparing BE with CA.
Randomized trials comparing BE with PA Four randomized, controlled clinical treatment trials comparing BE with PA have been published. [27] [28] [29] [30] Three of the four trials used 200 mg per kg of PA for the first dose and subsequent doses were given at 100 mg kg À1 . In the study by Baroutis et al., 28 three animal-derived surfactants (BE, PA and SF RI1) were compared and these investigators used 100 mg kg À1 for the initial as well as for subsequent doses in all three surfactant groups. All four trials showed a faster weaning of supplemental oxygen in the PA-treated group when compared with treatment with BE. In the trial by Ramanathan et al., 29 infants were randomized to 100 or 200 mg kg À1 for the initial dose of PA and 100 mg kg À1 for the initial dose of BE. All infants received 100 mg kg À1 of PA or BE for subsequent doses. The prespecified mortality at 36 weeks post-menstrual age among preterm infants p32 weeks was (Figure 1 ). When mortality results from two of the four studies 27, 29 were combined in a meta-analysis, mortality was significantly lower in the PA-treated group when compared with that in the BE-treated group (OR 0.35, 95% CI 0.13, 0.92). 33 Need for additional doses were also significantly lower in the PA-treated group when compared with that in the BE-treated group in two of the four trials 29, 30 ( Figure 2 ). In summary, results from randomized, controlled clinical trials comparing animal-derived surfactants show survival advantage, decreased need for additional doses and cost benefits in favor of PA when compared with BE. There were no differences observed in any of the trials comparing BE with CA.
Retrospective studies comparing BE, CA and PA Results from two retrospective studies have been published or presented. Clark et al. 31 published a retrospective study using data extracted from their administrative database. This study was primarily carried out to address the potential for a Type I error in the prospective randomized trial published in 1997. 25 A total of 5169 records were studied and 300 infants were of <600 g birth weight. The differences in mortality reported earlier from the randomized, controlled trial in a subgroup of patients of <600 g body weight 25 were not observed in this retrospective study. In the second retrospective study that compared mortality differences from a large national database in the United States among preterm infants treated with BE, CA or PA, Ramanathan et al. 32 reported a significantly lower mortality among infants treated with PA when compared with that among those treated with BE or CA. They evaluated data from 13 234 preterm neonates treated with one of the three animal-derived surfactant preparations. Adjusted, all-cause mortality among preterm infants was significantly lower in the PA-treated group (6.08%) when compared with that among BE-(8.12%) or CA (8.44%)-treated neonates (P<0.0001 for both). In preterm infants <34 weeks, mortality rate was lower in the PA-treated group (7.5%) when compared with that in the BE-(9.6%) or CA (9.6%) (P<0.0001 for both) -treated group.
In summary, evidence from randomized controlled clinical trials, as well as retrospective studies, has shown that there are differences in mortality and dosing requirements among preterm infants treated with different animal-derived surfactants. Among the three commonly used animal-derived preparations worldwide, treatment with PA has been shown to be associated with a lower mortality and cost benefits when compared with BE or CA. These differences in outcome may be related to the differences in composition among the three animal-derived surfactants, namely, phospholipid content, volume, viscosity, plasmalogen content and/or anti-inflammatory properties. Presently, animal-derived surfactants seem to be better than synthetic surfactants. Efforts to produce a synthetic surfactant that closely mimic the various components, including plasmalogens that are present in animal-derived surfactants, may be needed to achieve outcomes that are equivalent to or better than animal-derived surfactants. Disclosure R Ramanathan is a paid consultant for Dey, LP, but holds no equity. This paper was based on a talk presented at the Evidence vs Experience in Neonatal Practices Fifth Annual CME Conference that was supported by an unrestricted educational grant from Dey, LP.
